4-aminopyridine in the treatment of patients with multiple sclerosis. Long-term efficacy and safety.
OBJECTIVE
To study the long-term efficacy and safety of 4-aminopyridine in patients with multiple sclerosis.


METHODS
Case series, follow-up varying from 6 to 32 months.


METHODS
University referral center.


METHODS
Thirty-one patients with definite MS, 23 of them being exposed to long-term administration (6 to 32 months) of 4-aminopyridine, since they showed a favorable initial response to the drug.


METHODS
Long-term oral treatment with 4-aminopyridine in daily doses of up to 0.5 mg/kg of body weight.


METHODS
Neurologic functions and symptoms as reported by the patients; side effects.


RESULTS
Twenty of 23 patients who showed a favorable initial response benefited from long-term administration. Ambulation and fatigue (each in 13 patients) and visual function (in five patients) were most frequently reported to be improved. Three major side effects did occur during a follow-up of 406 patient months: a generalized epileptic seizure in two patients and hepatitis in one.


CONCLUSIONS
Although a substantial proportion of patients with multiple sclerosis seem to benefit from long-term administration of 4-aminopyridine, additional studies are needed to clarify the exact value of the drug.
Polman
C H
CH
Department of Neurology, Free University Hospital, Amsterdam, The Netherlands.
Bertelsmann
F W
FW
van Loenen
A C
AC
Koetsier
J C
JC
D015761:4-Aminopyridine / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009103:Multiple Sclerosis / Q000188:drug therapy*
D015761:4-Aminopyridine